CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu(HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (9) , 2714-2721
- https://doi.org/10.1158/1078-0432.ccr-06-2347
Abstract
Purpose: CD4+CD25bright regulatory T cells (Tregs) are increased in patients with several malignancies and correlate with disease stage and prognosis. Breast cancer patients represent a heterogeneous population with unpredictable disease progression even at advanced stages. Circulating Tregs in correlation with HER-2/neu (HER) status and treatment with chemotherapy, either alone or in combination with trastuzumab therapy, were monitored in advanced-stage breast cancer patients.Keywords
This publication has 41 references indexed in Scilit:
- Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors?Journal of Clinical Oncology, 2006
- Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast CancerClinical Chemistry, 2006
- Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★Breast Cancer Research and Treatment, 2006
- Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigenThe Journal of Experimental Medicine, 2005
- Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast CancersJournal of Clinical Oncology, 2005
- Altered Immunity Accompanies Disease Progression in a Mouse Model of Prostate DysplasiaCancer Research, 2005
- Chemotherapy: What Progress in the Last 5 Years?Journal of Clinical Oncology, 2005
- Prognostic and Predictive Factors for Breast Cancer: Translating Technology to OncologyJournal of Clinical Oncology, 2005
- Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast CancerClinical Cancer Research, 2004
- A Disquisition on Suppressor T CellsImmunological Reviews, 1975